Clinical Trial Centre, MATMED
Hodonín, 695 01, Czechia
NCT Number: NCT04646993
The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of anticoagulation after a first-ever episode of venous thromboembolism (VTE)
The general aim of the study is to evaluate the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulant therapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hodonín, 695 01, Czechia
The WHITE study is an international, non-profit, multicenter, observational, prospective and no profit study 3,200 subjects having experienced a first-ever episode of DVT of the lower limbs and/or PE, receive anticoagulation therapy for a period as recommended by international and/or local practice guidelines will be enrolled across all the countries participating to the study.
When this recommended period expires, the attending physician has to decide whether to continue with anticoagulation, switch to anti-thrombotic of another class, or stop any prophylactic pharmacological treatment.
The primary objective of the study is the evaluation of the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulation therapy.
The secondary objective is the collection of data during the follow-up: the frequency of thromboembolic complications, of bleeding complications, or death from any cause.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From the end of the 3rd month to the end of 12th month of anticoagulant treatment
Registration of number of patients who continue or stop the treatment; registration of type reasons guiding the attending physician's decision on the management of secondary prevention (eg: Bleeding score, laboratory test, presence of residual vein trombosis, risk or recurrence)
Time frame: Frome the first day of enrollment up to 24 monhts
the frequency of thromboembolic complications, of bleeding complications, or death from any cause monitored during the follow-up.
Arianna Anticoagulazione Foundation
Other
Which Decision After a First Venous Thromboembolism? The WHITE Study
Acronym: WHITE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689136
Cardiovascular Diseases, Deep Vein Thrombosis
Tunis, Tunisia
View Trial DetailsNCT04737954
Cardiovascular Diseases, Deep Vein Thrombosis
Hamburg, Germany
View Trial DetailsNCT05351749
Arrhythmias, Cardiac, Atrial Fibrillation
Ann Arbor, Michigan, United States
View Trial DetailsNCT04168203
Cardiovascular Diseases, Deep Vein Thrombosis
Boston, Massachusetts, United States
View Trial Details